Lonza Group Stock (CH0013841017): Dividend Ex-Date Set for May 13, 2026

Lonza Group AG goes ex-dividend on May 13, 2026, with a payment of 0.31867 USD per share via its ADR. The Swiss CDMO confirms ongoing robust segment momentum amid a confirmed outlook for nearly 20% sales growth.

Lonza Group AG goes ex-dividend on May 13, 2026, with a dividend of 0.31867 USD per share for its unsponsored ADR, as announced in recent market updates. This payout underscores the company's commitment to shareholder returns amid strong operational performance in its contract development and manufacturing organization (CDMO) business.

As of: May 05, 2026

By the AD HOC NEWS Editorial Team – Equity Coverage.

At a Glance

• Name: Lonza Group
• ISIN: CH0013841017
• Sector/Industry: Healthcare / Life Sciences Tools & Services
• Headquarters/Country: Basel, Switzerland
• Primary Exchange: SIX Swiss Exchange (SWX:LONN)
• Trading Currency: CHF

How Lonza Group Makes Money: The Core Business Model

Lonza Group operates as a global CDMO, providing integrated services from drug development to commercial manufacturing for biopharmaceutical companies. The company focuses on biologics, cell and gene therapies, and small molecules, generating revenue through long-term contracts with pharma and biotech clients.

In the first half of 2025, Lonza reported sales of CHF 3.6 billion at constant exchange rates, reflecting 19% growth year-over-year. Core EBITDA margin reached 29.6% in that period, supporting robust profitability in its CDMO segments.

The business model relies on high barriers to entry, including specialized facilities and regulatory expertise, enabling recurring revenue from capacity reservations and milestone payments.

Lonza Group's Key Revenue and Product Drivers

Lonza's revenue is driven by its Biologics and Cell & Gene Technologies segments, which benefit from increasing demand for outsourced manufacturing. For full year 2025, the company projects CDMO sales growth of 20-21% at constant exchange rates, with core EBITDA margin near 30%.

First quarter 2025 performance showed strong momentum across segments, contributing to the confirmed full-year outlook. Total revenue for 2025 reached 6.53 billion CHF, with net income of 949 million CHF.

Key drivers include expansions in modular manufacturing and partnerships for advanced therapies, positioning Lonza to capture growth in the biologics market.

Industry Trends and Competitive Landscape

The CDMO sector is expanding due to rising complexity in biopharma production and capacity constraints at innovator companies. Lonza competes with players like Catalent and Samsung Biologics in biologics manufacturing.

Global demand for cell and gene therapies is accelerating, with Lonza's specialized platforms providing a competitive edge. Industry analysts note robust segment momentum supporting Lonza's growth projections.

Market dynamics favor CDMOs with end-to-end capabilities, where Lonza's integrated offerings differentiate it from pure-play contract manufacturers.

Why Lonza Group Matters to US Investors

Lonza Group trades in the US via OTC symbol LZAGY, providing US investors access to its CHF-denominated shares on the SIX Swiss Exchange. The ADR structure facilitates dividend payments in USD, as seen with the upcoming 0.31867 USD per share ex-date on May 13, 2026.

With exposure to US biotech clients and facilities in the United States, Lonza derives significant revenue from North American markets. Currency risk exists due to CHF trading, but strong fundamentals appeal to investors seeking healthcare growth plays.

Lonza's inclusion in global indices and partnerships with US pharmas enhance its relevance for diversified portfolios focused on life sciences.

Which Investor Profile Fits Lonza Group – and Which Does Not?

Investors interested in structural growth within biopharma outsourcing may find alignment with Lonza's CDMO model and confirmed 20%+ sales trajectory. Those prioritizing stability in healthcare subsectors with high technical moats often monitor such names.

Profiles seeking high dividend yields or cyclical industrials may look elsewhere, given Lonza's focus on reinvestment for capacity expansion. Short-term traders focused on volatility might prefer other segments over this steady compounder.

Longer-horizon investors tracking innovation in cell and gene therapies represent a core audience for Lonza's developments.

Risks and Open Questions for Lonza Group

Biotech funding cycles can impact client pipelines, potentially affecting new contract inflows. Lonza's debt-to-equity ratio stands at 0.42, with liquidity supported by a current ratio of 2.24.

Regulatory hurdles in advanced therapies pose execution risks, alongside competition for large-scale projects. Quick ratio of 1.77 indicates solid short-term coverage.

Currency fluctuations between CHF and USD influence ADR performance for US investors, warranting attention to forex trends.

Key Events and Outlook for Investors

Lonza's next earnings are scheduled for January 28, 2026, providing updates on full-year 2025 results and 2026 guidance. The dividend ex-date on May 13, 2026, marks a near-term catalyst for income-focused holders.

Ongoing capacity expansions and segment momentum support the reiterated outlook for 20-21% CDMO sales growth. Investors should track Q4 2025 performance leading into the January report.

What to Watch Next

• May 13, 2026: Ex-dividend date (0.31867 USD ADR)
• Jan 28, 2026: Earnings release

Conclusion

The May 13, 2026, ex-dividend date for 0.31867 USD per ADR share highlights Lonza Group's shareholder return strategy. Strong Q1 2025 results and a confirmed 20-21% sales growth outlook reinforce operational strength. US investors gain exposure via LZAGY amid favorable CDMO trends.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.